Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT02000102
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Key Dates

First listed
Dec 3, 2013
Start date
Sep 30, 2013
Status verified
Nov 2014
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014

Study Design

Enrollment
14 participants (actual)

Arms

  • Arm: Diabetic Macular Edema Patients Switched to Aflibercept

Primary Outcome Measure

Visual Acuity [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Byers Eye Institute at StanfordPalo AltoCalifornia94303-

Find similar trials in Palo Alto, CA

Nationwide
Diabetic retinopathy trialsOphthalmology trialsRetina trials
By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Byers Eye Institute at Stanford· Palo Alto, CA

Related Studies